PIN74 Cost Savings Due to Antibiotic Prescription Related to Quick C-Reactive Protein Testing  by Tesar, T. & Babela, R.
tion of 4,531 deaths from IPD and 34,648 deaths from hospitalized pneumonia over
10 years. Compared to no vaccination, PCV13 vaccination would be cost-effective at
RM21,998 per QALY gained from the societal perspective. Compared to PCV10,
PCV13 vaccination would avoid an additional 9,651 cases of IPD, 392,684 and
980,434 cases of hospitalized and non-hospitalized pneumonia respectively, and
81,118 cases of AOM with the prevention of 18,736 deaths. Compared to PCV10,
PCV13 vaccination would be cost-effective at RM6,315 per QALY gained.
CONCLUSIONS: Universal pediatric PCV13 vaccination in Malaysia was estimated
to reduce the burden of pneumococcal diseases and is expected to be cost-effective
compared with both no vaccination and PCV10.
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OBJECTIVES: Pharmacological approaches available in chronic hepatitis B (CHB)
are based on 48-weeks finite course of peg-interferon (PEG) or continuous admin-
istration of nucleoside analogues. Recent studies gave way to early identification of
responders to PEG with a stopping rule based on virologic and serologic markers at
week 12. Objective of this study is the cost-effectiveness analysis of HBeAg-nega-
tive CHB treatment with PEG with stopping rule and switch to current most effec-
tive analogues, entecavir (ETV) or tenofovir (TDF) in Italy. METHODS: A Markov
model was developed in the states: CHB, virologic response, relapse, HBsAg clear-
ance, compensated and decompensated cirrhosis, hepatocarcinoma, liver trans-
plant, post-liver transplant and death. A systematic review of the clinical and
economic literature was performed to find appropriate information. The simulated
strategies were: 1) No treatment; 2) PEG first-line followed by switch to ETV/TDF for
patients either meeting w-12 stopping rule or not responding/relapsing after the
complete course; 3) First-line ETV/TDF in CHB before progression to compensated
cirrhosis (CC); 4) ETV/TDF treatment delayed until CC. ETV and TDF were consid-
ered alternatively for a total of 8 strategies. Outcomes were quality-adjusted life
years (QALY) and costs, calculated from the Italian NHS perspective. RESULTS: The
strategies provided 10.4, 15.3, 15.0, 12.0 QALYs, for no-treatment, PEGETV/TDF,
ETV/TDF-in-CHB and ETV/TDF-in-CC. No meaningful difference in outcomes was
found when ETV or TDF were considered. The average per-patient lifetime cost was
€27,090, €59,270, €69,050, €33,520 with no-treatment, PEGTDF, TDF-in-CHB and
TDF-in-CC. Costs using ETV were 19%-48% higher. PEGTDF was dominant with
respect to TDF-in-CHB and with an ICER of €6,590/QALY and € 7,750/QALY when
compared to no-treatment and TDF-in-CC.CONCLUSIONS:Non treatment or treat-
ment delayed until cirrhosis yielded the poorest outcomes. The strategy of a PEG
first-line with the stopping rule showed a convenient cost-effectiveness profile,
providing the optimal trade-off between clinical efficacy and costs.
PIN71
THE POTENTIAL PUBLIC HEALTH BENEFIT OF PNEUMOCOCCAL CONJUGATE
VACCINES IN KAZAKHSTAN
Nurgozhin T1, Yermekbaeva B1, Topachevskyi O2
1Nazarbayev University, The Center for Life Sciences, Astana, Kazakhstan, 2GlaxoSmithKline
Vaccines, Wavre, Belgium
OBJECTIVES: To evaluate cost–effectiveness of pneumococcal vaccination with
10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate
vaccine (PHiD-CV) compared with 13-valent pneumococcal conjugate vaccine
(PCV-13) and no vaccination in Kazakhstan. METHODS: A steady state model with
a one-year time horizon was developed to project the impact of vaccination on the
incidence of pneumococcal and non-typeable Haemophilus influenzae infections in
children aged 0-10 years. Disease incidence rates for meningitis, bacteremia, pneu-
monia and acute otitis media (AOM) were based on data from the Ministry of
Health, benchmarked with other countries and validated by a group of local ex-
perts. Pneumococcal serotypes distribution is based on 4,752 samples reported by
GAVI for Asian region. Serotypes coverage rates of 65.67% and 69.5% for PHiD-CV
and PCV-13, payer perspective, 31 schedule, no herd protection were assumed.
RESULTS: PHiD-CV and PCV-13 are projected to prevent more cases of invasive
disease (278; 294 respectively), and pneumonia hospitalizations (12270; 12270 re-
spectively) compared to no vaccination. PHiD-CV and PCV-13 are projected to pre-
vent additional myringotomies (1920; 949 respectively) and GP visits due to AOM
(70,057; 34,639 respectively) compared to no vaccination strategy. No difference in
absolute number of death was projected when PHiD-CV is compared with PCV-13.
Vaccinating a birth cohort with PHiD-CV or PCV-13 is expected to generate 4,541
and 4,388, respectively, more QALYs compared to no vaccination. At vaccine steady
state PHiD-CV is projected to generate KZT 1.2M in direct medical cost-savings
compared with PCV-13. Sensitivity analyses indicate that incidence rate of menin-
gitis and bacteremia are the most sensitive parameters in the model.
CONCLUSIONS: Pneumococcal conjugate vaccines would be cost effective inter-
ventions for Kazakhstan. However, PHiD-CV dominates PCV-13 because it has a
larger potential QALY gain and higher cost offset related to the additional benefits
due to AOM reduction.
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OBJECTIVES: To evaluate the cost-effectiveness of palivizumab as respiratory syn-
cytial virus prophylaxis in preterm infants born at 35 weeks’ gestation or earlier,
and to determine how the cost-effectiveness of prophylaxis differs among sub-
groups according to risk factors for RSV-related hospitalization. METHODS: A de-
cision analytic model was designed to assess the cost-effectiveness of prophylaxis
with palivizumab for preterm infants born at  35 weeks’ gestational age and  6
months of age compared with no prophylaxis. And by using this model, subgroup
analyses were conducted to evaluate cost-effectiveness for children with different
risk factors related to RSV hospitalization (gestational age, age at the start of the
RSV season, with chronic lung disease, having siblings at school, discharge through
RSV season). RESULTS: The expected costs and QALYs for preterm infants with
palivizumab prophylaxis were higher than those with no prophylaxis. The incre-
mental cost-effectiveness ratio (ICER) for the preterm infants was 19,928,984 KRW
per QALY. The cost-effectiveness of palivizumab varied among the subgroups with
different risk factors. The prophylaxis with palivizumab may be cost-effective
(based on a threshold of 20,000,000 KRW per QALY) for preterm infants with one or
more risk factors according to the age at the start of the RSV season. The prophy-
laxis with palivizumab for preterm infants was cost-effective for infants under 3
months old with 1 risk factor, infants under 9 months old with 2 risk factors, and
infants under 15 months old with 3 risk factors. CONCLUSIONS: This study found
that prophylaxis with palivizumab is a cost-effective strategy for preterm children
compared with no prophylaxis and has different cost-effectiveness according to
the risk factors because of the influence on the risk of RSV hospitalization. There-
fore, it is reasonable to recommend the use of palivizumab for preterm infants in
subgroup with cost-effectiveness considering the risk factors.
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OBJECTIVES: To calculate the direct medical costs associated with HCV health
states by eliciting expert opinion. METHODS: Portuguese-specific annual direct
medical costs of HCV health states were estimated based on a national expert panel
with 8 clinicians experienced in HCV treatment at the national level. We adopted a
two-stage modified Delphi technique: First, experts independently answered ques-
tions concerning the resource use associated with each HCV-related health state.
Secondly, a consensus meeting was held where experts were encouraged to revise
their earlier answers after the panel discussion. The annual cost for each health
state of HCV disease was thereafter obtained by multiplying unit costs with the
consensus scores for each resource use. Unitary costs were obtained through na-
tional official sources. Fibrosis (F0-F3), compensated cirrhosis (CC), decompensated
cirrhosis (DC), hepatocellular carcinoma (HCC) and liver transplantation were set
as the different HCV health states with relevance for clinical and economic
research. RESULTS: Estimated annual costs per HCV health state were the follow-
ing: fibrosis (F0-F3) was €580, in advanced liver disease, CC was €1,156, whereas DC
was €8,222 for the first year and €9,085 for subsequent years. For HCC first year, the
annual cost was €20,749, whilst €19,088 for subsequent years. For liver transplant,
first year cost was €112,072, while for subsequent years it was €7,558. The consid-
erable difference between the costs associated with the first and subsequent years
is due to the transplant procedure being the cost driver for this health state.
CONCLUSIONS:Overall Cost of illness associated with HCV infection is substantial
in Portugal and increases throughout the liver disease health states. Strategies
aiming to treat HCV infection have the potential to decrease the disease progres-
sion and subsequent total costs associated with HCV-related liver disease. The
results from our research highlight this point and may support cost-effectiveness
analysis in the evaluation of those strategies.
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OBJECTIVES: The excessive and often unnecessary prescription of antibiotics and
the resulting increase in antibiotic resistance poses a serious medical problem. The
analysis provides data for assessing a health insurance company’s strategies aim-
ing to optimize antibiotic prescribing due to a quick C-reactive protein testing.
METHODS: Within a period of 22 months (January 2009 – October 2010), in a pop-
ulation sample of 365 690 insured persons from Slovakia, a connection was studied
between availability of a quick C-reactive protein testing as a service furnished by
medical care providers and a final cost of antibiotic treatment. A health insurance
fund provided data for this analysis. RESULTS: Higher consumption of antibiotics
can be linked to higher resistance to antibiotics. On the other hand this linkage is
not linear. In the analysis, the average expenditure per 1 patient at the level of 1.12
€ can be seen within GPs, where a quick C-reactive protein testing is available. On
the other hand, the average expenditure per 1 patient at the level of 1.35 € can be
seen within GPs, where a quick C-reactive protein testing is not available. The
average expenditure per 1 pediatric patient at the level of 1.64 € can be seen within
pediatric medicine, where a quick C-reactive protein testing is available. However,
the average expenditure per 1 pediatric patient at the level of 2.33 € can be seen
within pediatric medicine, where a quick C-reactive protein testing is not available.
Based on the analysis, we can finalised that in the case of an appropriate use of
C-reactive protein testing with the monitored sample of 365 690 insured persons
within the above mentioned period of 22 months, financial resources in a total
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amount of 340 000 € could have been saved. CONCLUSIONS: Adherence to princi-
ples of good antibiotic policies leads to fundamental short and long term financial
savings within the budget of a health insurance fund.
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OBJECTIVES: Clostridium difficile infection (CDI) can lead to several complications
from mild diarrhoea to toxic megacolon. The objectives of this study were to: 1)
evaluate standard Time trade-off (TTO) and chain TTO techniques for eliciting
utility of CDI-related chronic and temporary health states; 2) compare those values
with those from Healthcare Professional (HCP) EQ-5D valuation; 3) evaluate meth-
ods of calculating utilities for health states worse than death (WTD). METHODS:
Ten health state vignettes were developed from literature with input from HCPs.
Participants from the UK public were interviewed: 50 for the pilot and 100 for the
main study. Each participant provided sociodemographic information, ranking of
health states by preference and responses to a Computer-Assisted Personal Inter-
view TTO protocol for all states considered. HCPs provided EQ-5D data. Methods to
apprehend the impact of extreme negative utilities were appraised: truncation and
monotonic transformation.RESULTS:Temporary health state utilities ranged from
(mean and (/) median from non transformed method; mean and median (/) from
monotonically transformed method): -2.70/0.7;0.39/0.6 for mild diarrhoea to
-32.50/-1.1; -0.23/-0.5 for colectomy. Chronic health state ranged from: -2.37/0.5;
0.35/0.5 for chronic diarrhoea to -7.98/0;-0.13/0 for chronic renal failure. Population
valuations were more severe for most health states when compared with HCP
values. CONCLUSIONS: While transformation has an important impact on results,
nowadays there is no reliable measure of utilities for CDI-health states. The pro-
portion of participants judging health states as WTD was unexpectedly high; ques-
tioning the suitability of face-to-face TTO interview in this disease area. The mono-
tonic transformation was convenient but lacks theoretical grounding. Other
methods like Lead Time trade-off could add value to similar research.
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OBJECTIVES: To investigate health related quality of life (HRQOL) in non-engaging
HIV infected intravenous drug users (IVDUs) over a one year time period.
METHODS: This was a prospective observational cohort study of non-engaging
adult HIV infected IVDUs registered for care at an inner city HIV unit (non-engage-
ment defined as missing  2 HIV outpatient appointments over one year or not
attending outpatients for six months). EQ-5D, SF-36, Hospital Anxiety Depression
scale (HADs), clinical and substance misuse data were collected on a six monthly
basis. Regression models were fitted to identify the statistical relationship between
utility and HADs. The relationship between measures was assessed using spear-
man’s correlation for non-parametric data. RESULTS: Fifty-two patients were in-
cluded (125 observations). Sixty two percent were male with a mean age of 37 yrs.
The mean anxiety value was 10.9 (borderline anxiety), and mean Depression score
was 9.3 (borderline depressed). The mean EQ5D utility score was 0.51(95% CI: 0.45 –
0.59) Fifteen patients (12%) had an EQ5D utility worse than death of whom 14 (93%)
were anxious and 13 (86%) were depressed. The mean SF6D utility was 0.53 (95%CI:
0.51 – 0.55). Mean Physical component score (PCS) was 53.91, and mental compo-
nent score (MCS) was 34.03. Role physical had the lowest mean score at 28.07, and
was significantly correlated with anxiety (spearman’s correlation -0.318, signifi-
cant at 0.01 level, 2 tailed), depression (spearmans’s correlation -0.316, significant
at 0.01 level, 2 tailed), virological suppression (spearman’s correlation -0.194 sig-
nificant at 0.05 level, 2 tailed) and HIV viral load (spearman’s correlation -0.207,
significant at 0.05 level, 2 tailed). CONCLUSIONS: HRQOL was severely reduced in
this non-engaging HIV infected IVDU population. Whilst HCV co-infection and
substance misuse did not affect the HRQOL, anxiety and depression had a signifi-
cant impact upon it.
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OBJECTIVES: Cytomegalovirus (CMV) is responsible directly or indirectly for an
increase of mortality and morbidity in patients with solid organ transplantation
(SOT) and hematopoietic stem cell transplantation (HSCT). Our aim was to identify
HRQoL dimensions affected by CMV infections and management after HSCT or
SOT. METHODS: A literature review on transplanted patients’ HRQoL through the
EMBASE database was performed. We also looked for issues raised by patients in
specialized forums. Individual interviews were conducted with 4 clinical experts
and 20 patients, divided equally into HSCT and SOT groups. Clinical practitioners
were asked to identify key concepts attributable to the CMV-disease (symptoms) or
antiviral side effects versus transplantation-related. Patients were asked to cite
important concepts and rate them. All patient responses were coded. Code fre-
quency and bother ratings were used to identify salient patient experiences.
RESULTS: Preliminary analysis suggests that it is difficult to isolate the effects of
the CMV infection and the antiviral treatment due to other untolerated medica-
tions (e.g. immunosuppressive drugs) and/or the patient’s underlying medical con-
dition. Key reported symptoms include fever and (worsened) tiredness. Tiredness
was often described as being related to physical activity limitation. Key areas im-
pacted by CMV infection and CMV treatment included physical activity and mobil-
ity limitations, as well as mental fatigue and stress. Practitioner judgments helped
classify the different concepts into one of 3 categories, CMV-disease symptom,
treatment side effects, and psychological concerns. CONCLUSIONS: The CMV im-
pact was found to be quite heterogeneous between patients as it seems to be
dependent on type of transplantation, experience of symptomatic infection and
tolerance of antidepressants. This qualitative study suggested that physical activ-
ity, mobility, mental fatigue, and stress are key QoL dimensions affected by CMV
management, infections and treatments in transplanted patients.
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Primary immunodeficiency (PI) constitutes a group of disorders involving a primary
defect in the immune system often requiring lifelong Immunoglobulin (IG) therapy
which can be administered intravenously (IGIV) or subcutaneously (IGSC).
OBJECTIVES: To quantify patient and caregivers preferences for administration
attributes of IG treatments. METHODS: Adult patients and caregivers of children
with PI from 21 non-U.S. countries recruited via national member organisations
completed a web-enabled, choice-format survey. The conjoint analysis quantified
the preferences of attributes presented to the respondents. The preference weights
for each sample were scaled between 0 and 10. The vertical distance between
adjacent preference weights indicated the relative importance of moving from one
level of an attribute to an adjacent level of that attribute. RESULTS: A total of 216
patients and 84 caregivers completed the survey. Patients and caregivers signifi-
cantly preferred monthly to weekly, home setting to doctor’s office/hospital/ clinic,
shorter duration, and fewer needle sticks of IG treatment (P  0.05). There was a
difference in the ranking of these attributes between IGIV and IGSC users. IGIV
users indicated frequency as the most important attribute followed by number of
needle sticks, duration and home setting while IGSC users indicated home setting
as the most important attribute followed by duration, self administration, number
of needle sticks, and frequency. CONCLUSIONS: IG treatments that provide the
comprehensive option of a monthly frequency, home setting, shorter duration, and
fewer needle sticks may address the needs of both PI patients and caregivers,
although ranking of these attributes may be different between the IGIV and IGSC
users.
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OBJECTIVES: Hepatitis C virus (HCV) infection may cause cognitive impairment,
but no studies have focused specifically on cognitive impairment stemming from
Alzheimer’s disease. The purpose of this study was to investigate the potential
increased risk for Alzheimer’s disease in HCV-infected patients. METHODS: We
conducted a population-based cohort study from the Taiwan National Health In-
surance Research Database. From all potential participants aged fifty years or
more, a total of 117,098 matched (1:1) pairs of HCV-infected patients and non-HCV-
infected patients were included. Each subject was individually tracked from 1997 to
2009 to identify incident cases of Alzheimer’s disease (onset in 1999 or later). Cox
proportional hazard regressions were employed to calculate the hazard ratios (HRs)
and 95% confidence intervals (CIs) for the association between HCV infection and
Alzheimer’s disease in the HCV-infected cohort. RESULTS: There were 830 cases of
Alzheimer’s disease reported in the HCV cohort during follow-up periods of
1,122,436.9 person-years, with incidence rates of 73.9 cases per 100,000 person-
years (95% CI, 69.1-79.2). The multivariate-adjusted HR for Alzheimer’s disease was
1.14 (95% CI, 1.02-1.26) for HCV-infected patients. The HR for HCV-infected patients
in their sixties (1.18, p  0.05) was higher than for other subgroups. There were
5,243 HCV-infected patients (4.48%) who completed antivirus therapy. The HR of
treated patients was 0.31 (95% CI 0.15-0.67) after adjusting for age, gender, income,
urbanization and the presence of other medical diseases. CONCLUSIONS: HCV
infection may increase the risk for Alzheimer’s disease. HCV antiviral therapy
could lower the risk of AD in HCV-infected patients.
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